Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Collegium Pharmaceutical ( (COLL) ) is now available.
On January 8, 2026, Collegium Pharmaceutical issued 2026 financial guidance, projecting net product revenue between $805 million and $825 million, including $190 million to $200 million from ADHD drug Jornay PM, and adjusted EBITDA in the range of $455 million to $475 million, signaling continued reliance on Jornay PM as its primary growth driver. Management highlighted that 2025 delivered record growth and reiterated that they are on track to meet the increased 2025 guidance provided in November—$775 million to $785 million in net revenue and $460 million to $470 million in adjusted EBITDA—while recent moves such as refinancing via a $980 million syndicated credit facility and an authorized generic partnership with Hikma for Nucynta and Nucynta ER are expected to strengthen the balance sheet, lower interest costs, and create new revenue streams, albeit amid ongoing regulatory, competitive, and market-access risks outlined by the company.
The most recent analyst rating on (COLL) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.
Spark’s Take on COLL Stock
According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.
The score is driven primarily by solid financial execution and cash flow, supported by a strong earnings call with raised guidance and record quarterly performance. Offsetting factors include high leverage and a higher P/E valuation, while technicals are constructive but currently mixed/neutral in the short term.
To see Spark’s full report on COLL stock, click here.
More about Collegium Pharmaceutical
Collegium Pharmaceutical is a U.S.-based biopharmaceutical company focused on treatments for serious medical conditions, with a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business led by Jornay PM, a differentiated ADHD therapy. The company’s strategy centers on expanding its commercial portfolio—particularly around Jornay PM—while deploying capital in a disciplined manner from its headquarters in Stoughton, Massachusetts.
Average Trading Volume: 499,903
Technical Sentiment Signal: Buy
Current Market Cap: $1.46B
Learn more about COLL stock on TipRanks’ Stock Analysis page.